In total, 9 patients with HAE-nC1-INH initiated berotralstat therapy; 6 are included in this analysis, 2 continued to receive therapy but did not have 6-month follow-up data, and 1 patient at the Grenoble center had discontinued berotralstat within 6 months of its introduction as a result of GI adverse effects. Here, COL18A1 is linked to hereditary angioedema.